Tuberculosis (TB) remains one of the leading causes of death from infectious diseases globally, with more than 1.6 million deaths annually. While the BCG vaccine exists, it offers limited protection, especially in adults.
In 2025, South Africa becomes one of the first countries to initiate phase 2 clinical trials of a new and more effective TB vaccine.
🧪 A Medical Breakthrough for Africa
This next-generation vaccine aims to provide stronger and longer-lasting protection, particularly for adults in high-risk regions. The trials are taking place in hospitals across Johannesburg and Cape Town.
They involve healthy and at-risk volunteers to evaluate both safety and efficacy.
🏥 Global Partnership and Local Support
The project is led by an international consortium of researchers, in collaboration with South African institutions such as the University of the Witwatersrand, and backed by the Bill & Melinda Gates Foundation, the World Health Organization (WHO), and the South African Medical Research Council.
🔬 A Crucial Step in Public Health
If results are positive, the vaccine could be rolled out by 2027 in large-scale immunization campaigns, especially across sub-Saharan Africa.
South Africa once again demonstrates its leadership in medical innovation on the continent in the fight against deadly diseases.
